Literature DB >> 9582527

Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.

J S de Jong1, P J van Diest, P van der Valk, J P Baak.   

Abstract

Growth factors may play an important role in tumour growth and angiogenesis by their influence on tumour cell proliferation or their effect on neovascularization. The aim of the present study was to determine which of the growth factors, growth-inhibiting factors, and their receptors investigated in a previous study are correlated with proliferation and angiogenesis in invasive breast cancer, with emphasis on the impact of possible autocrine and paracrine loops. Five growth factors and their receptors: platelet-derived growth factor A chain (PDGF-AA) and PDGF alpha receptor (PDGF alpha R), PDGF-BB and PDGF beta receptor (PDGF beta R), transforming growth factor alpha (TGF alpha) and its receptor epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1/KDR; two growth-inhibiting factors: transforming growth factor beta-1 (TGF beta 1) and TGF beta 2 and their receptor couple TGF beta R-I and TGF beta R-II; and basic fibroblast growth factor (bFGF) were stained in 45 cases of invasive breast cancer by standard immunohistochemistry on frozen sections. Staining in tumour cells, stromal cells, and endothelial cells was scored as negative or positive. Proliferation was determined by assessment of the mitotic activity index (MAI) and the degree of angiogenesis was measure by counting the number of microvessels (microvessel density: MVD) in the most vascularized area of the tumour. bFGF and EGFR showed positive correlations with the MAI, while TGF beta 2 showed a negative correlation. Expression of bFGF, TGF alpha, TGF beta 2, and EGFR correlated positively with the MVD. Co-expression of the TGF alpha/EGFR growth factor/receptor combination showed a stronger correlation with the MAI and the MVD than EGFR or TGF alpha alone, and the TGF beta 2/TGF beta R-I/TGE beta R-II combination showed a positive correlation with the MVD. In conclusion, the expression of several growth factors, growth factor receptors and growth-inhibiting factors showed correlations with the rate of proliferation and the degree of angiogenesis in invasive breast cancer. Some growth factor/receptor combinations showed stronger correlations with proliferation and angiogenesis than the growth factor or receptor alone, pointing to the importance of possible auto- and paracrine loops for stimulation of proliferation and angiogenesis by growth factors and their receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582527     DOI: 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  54 in total

Review 1.  Angiogenic molecules and mechanisms in breast cancer.

Authors:  I Wu; M A Moses
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

Review 2.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

3.  Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology.

Authors:  Em Dietrich; K Antoniades
Journal:  Hippokratia       Date:  2012-07       Impact factor: 0.471

Review 4.  Stromal cells and integrins: conforming to the needs of the tumor microenvironment.

Authors:  Aimee Alphonso; Suresh K Alahari
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  Pathway analysis using random forests with bivariate node-split for survival outcomes.

Authors:  Herbert Pang; Debayan Datta; Hongyu Zhao
Journal:  Bioinformatics       Date:  2009-11-18       Impact factor: 6.937

6.  Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma.

Authors:  J W Slaton; K Inoue; P Perrotte; A K El-Naggar; D A Swanson; I J Fidler; C P Dinney
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

7.  First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

Authors:  Vivek Subbiah; Muhammad Rizwan Khawaja; David S Hong; Behrang Amini; Jiang Yungfang; Hui Liu; Adrienne Johnson; Alexa B Schrock; Siraj M Ali; James X Sun; David Fabrizio; Sarina Piha-Paul; Siqing Fu; Apostolia M Tsimberidou; Aung Naing; Filip Janku; Daniel D Karp; Michael Overman; Cathy Eng; Scott Kopetz; Funda Meric-Bernstam; Gerald S Falchook
Journal:  JCI Insight       Date:  2017-04-20

8.  Giant cell formation in sarcoidosis: cell fusion or proliferation with non-division?

Authors:  T C M Th van Maarsseveen; W Vos; P J van Diest
Journal:  Clin Exp Immunol       Date:  2008-12-05       Impact factor: 4.330

9.  Long noncoding RNA AK056155 involved in the development of Loeys-Dietz syndrome through AKT/PI3K signaling pathway.

Authors:  Bo Yu; Long Liu; Huan Sun; Yu Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance.

Authors:  Jian-Xian Yu; Xiao-Tun Zhang; Yong-Qiang Liao; Qi-Yi Zhang; Hua Chen; Mei Lin; Shant Kumar
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.